Our findings suggest that the combination of Enz with targeting RPS6KC1 or the ferroptosis inducer Erastin may represent a promising therapeutic strategy for PCa patients exhibiting resistance to Enz. Here, RPS6KC1 is linked to posterior cortical atrophy.